Literature DB >> 7515337

Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules.

D Rigal1, C Vermot-Desroches, S Heitz, J Bernaud, F Alfonsi, J C Monier.   

Abstract

Polyspecific IgG given intravenously at high dose (IVIG) are increasingly used as an immunomodulating therapy in autoimmune diseases. However, very few studies have dealt with the action of IVIG on the expression of the leukocyte markers. During a clinical trial in which 13 young and healthy women received IVIG to prevent unexplained recurrent abortions we have evaluated by flow cytometry the action of IVIG on 17 clusters of leukocyte differentiation (CD). We found that the IVIG perfusions (0.5 g/kg) induced an increase in the number of polymorphonuclear and monocyte cells in the peripheral blood. This effect lasted 8 days. The IVIG treatment had no effect upon T cell populations stained with antibodies specific for CD2, CD3, CD4, CD8 and on CD4+CD45RA+, CD4+CD29+, CD8+CD28+, CD8+CD28- subpopulations. A weak decrease in the B cell number was observed. The most striking phenomenon was the decrease in the number of CD56+ cells, whereas CD16+ and CD57+ cells were unaltered. By the double-staining technique we showed that CD56+CD16+ cells became CD56-CD16+ cells. Moreover, IVIG decrease the expression level of the LFA-1 molecule on monocytes and lymphocytes. The other adhesion molecules studied remained steady (CD11b, CD49d, CD49e, CD29, CD28, and CD62L). This study has shown that IVIG have no effect on 15 of 17 CD used but downmodulate two adhesion molecules playing a key role in the immune system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515337     DOI: 10.1006/clin.1994.1091

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  16 in total

Review 1.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 4.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

5.  Advances of intravenous immunoglobulin G in modulation of anti-fetal immunity in selected at-risk populations: science and therapeutics.

Authors:  O B Christiansen
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

6.  Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia.

Authors:  R M Aspalter; W A Sewell; K Dolman; J Farrant; A D Webster
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

7.  Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1.

Authors:  Jung-Eun Jang; Andrés Hidalgo; Paul S Frenette
Journal:  Circ Res       Date:  2012-03-13       Impact factor: 17.367

8.  7th International Immunoglobulin Conference: Immunomodulation.

Authors:  M G Danieli; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 9.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

10.  Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic proliferation of B cells.

Authors:  Ayane Hori; Takashi Fujimura; Seiji Kawamoto
Journal:  Cytotechnology       Date:  2018-04-02       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.